Objective. Clinically meaningful change in systemic sclerosis (SSc) related interstitial lung (SSc-ILD) disease is unknown. The aim of this study was to quantify change in pulmonary function as a predictor of outcome in SSc-ILD. Methods. All patients had SSc-ILD defined by HRCT chest. All PFTs during follow-up, including FVC (L), DLCO (ml/min/mmHg) and KCO (DLCO/alveolar volume ratio; DLCO/VA) (ml/ min/mmHg/L) were retrieved. The rate of change over the first four years, and percentage change in the first year of follow-up were used in ROC curve analysis to determine the best cut-off points to predict adverse outcome (home oxygen, lung transplantation, or death). Results. Among 264 patients, there were 49 events (38 deaths, 10 supplemental oxygen, one lung transplant) over a mean (±SD) follow-up of 3.0 (±1.7) years. The rates of decline over time and percentage change over one year in each of FVC, DLCO and KCO were predictive of adverse outcome. Stable PFTs over four years gave the optimal negative predictive values (NPVs) of 88-96%. The best sensitivity-specificity trade-off was a decline in FVC of 10% and in DLCO and KCO of 15% with NPVs of 92-93%. Conclusion. The course that SSc-ILD takes is evident within the first 1-4 years of follow up. Patients who have no decline in PFTs over 4 years have better outcomes. A decline within one year in DLCO or KCO of 15% or more is a poor prognostic factor, and identifies patients who should be monitored more closely and considered for therapy.
Introduction
Lung disease is one of the major causes of mortality in patients with systemic sclerosis (SSc) (1) (2) (3) (4) . While 65-91% of patients with SSc have changes of interstitial lung disease (SSc-ILD) on high resolution CT of the lung (HRCT) (5, 6) , this is not severe or progressive in all patients. We and others (7, 8) have shown that more extensive lung disease on HRCT at baseline and on follow-up, predicts a worse outcome in SSc-ILD. Serial pulmonary function tests (PFTs) including forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) divided by alveolar volume ratio (DLCO/ VA [KCO]) also predict outcome (2, 7) , and have the potential to predict disease progression before it becomes extensive on HRCT, without repeated exposure to radiation. Expert guidelines recommend frequent monitoring of lung function in the early years of SSc-ILD (9, 10) , although there are no established data on what is a clinically meaningful decline in these variables in SSc-ILD. Therefore, in this study, we sought to quantify change in pulmonary function as a predictor of disease outcome in SSc-ILD.
Methods

Patients
We included patients with SSc-ILD as defined by the presence of characteristic findings of fibrosis on HRCT, who were enrolled in the Australian Scleroderma Cohort Study (ASCS), a prospective multicentre study of risk and prognostic factors for cardiopulmonary outcomes in SSc. All patients fulfilled the ACR or Leroy/Medsger limited criteria for diagnosis of SSc (11, 12) . Written informed consent was obtained. The ASCS has been approved by the human research ethics committee of each of the participating centre (Royal Perth Hospital Ethics Committee; Royal Adelaide Hospital Research Ethics Committee; St Vincent's Human 
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Clinical and laboratory variables
All available serial PFTs were retrieved for each patient through detailed review of all medical records, including those from prior to enrolment in the ASCS. 'Baseline' PFT was the first retrievable PFT. PFT parameters including FVC (L), DLCO (ml/min/mmHg) and KCO, defined as DLCO by alveolar volume ratio (DLCO/VA) (ml/min/mmHg/L) were recorded. Demographic data included sex, age and smoking history. Disease related variables included duration of disease from the first non-Raynaud's phenomenon symptom, disease subtype (13) , overlap with other connective tissue diseases based on clinical features and where relevant, autoantibodies, and SSc-related and antibody profile. In addition, all serial lung HRCTs were obtained.
Evaluation of PFT parameters
Change in PFT values was assessed in several ways. Firstly, the rate of change over four years in the absolute value for each variable was calculated using a regression line of best fit for the variable plotted against time. The coefficient of regression was the slope of the line and represented the rate of decline. Secondly, percentage change in values relative to baseline over the first year of followup (±90 days) was determined.
Evaluation of HRCT scans
Where available, baseline lung HRCTs were scored using a staging system we have previously validated (7) . Specifically, each HRCT was graded based on the total extent of lung disease: <20% was scored as 'limited', >20% was scored as 'extensive' (8) .
Outcome variable
The primary outcome variable was a composite of death (all-cause), need for supplemental oxygen (ambulatory and/or continuous) or lung transplantation. In the ASCS, ambulatory oxygen DLCO: diffusing capacity of the lung for carbon monoxide; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; IQR: interquartile range; KCO: DLCO by alveolar volume ratio (DLCO/VA); PFT: pulmonary function test. * analysis limited to patients in whom there were 2 or more measurements of PFT variables in the first year; # relative to baseline; ** less than 5% decline relative to baseline.
is prescribed to patients with desaturation on exercise, measured by pulse oximeter, to an oxygen saturation (SpO2) ≤88%. Other indications are having an arterial partial pressure of oxygen ≤55 mmHg at rest or <60 mmHg at rest, with evidence of pulmonary hypertension or cor pulmonale (14) .
To enable time-to-event analysis, the date of 'first' occurrence of each outcome was recorded as either the date of death or lung transplantation, or the clinic date at which oxygen therapy was first prescribed in those who were alive and had not undergone lung transplantation at the time of the last clinic visit. For patients who remained outcome-free, data were censored at the last clinic visit.
Statistical analyses
Univariable Cox regression models were used to determine the relationship between each of rate of decline and percentage decline in each PFT variable, and event-free survival. Receiver operating characteristics (ROC) curves and diagnostic testing procedures were used to determine the best cut-off points to predict adverse outcomes.
In subgroup analysis of patients in whom the HRCT score was available at baseline, Kaplan-Meier (K-M) survival curves were used to determine the relationship between percentage decline in PFT and outcome, after adjustment for HRCT score (i.e. limited vs. extensive).
Results
Patient characteristics
Patient characteristics are presented in Table I . Among 1170 patients in the ASCS, 311 (26.6%) were recorded as ever having ILD; PFT data were retrievable in 262 of these patients. Mean (±SD) age and disease duration at baseline PFT were 57.6 (±11.9) and 12. Positive predictive values (PPVs) were less than 25% (Table VI) .
Percentage decline in variables over one year
The percentage changes over one year from baseline (±90 days) in FVC, DLCO and KCO were also significantly associated with deterioration or death in univariable modeling (HRs 
Stratifying by extent of disease on baseline HRCT lung
The extent of disease on HRCT scan of the lung at baseline enabled further stratification of patients' risk of adverse outcome beyond change in FVC over 1 year (Fig. 1) , though our analyses in this section were limited to only 60 patients who had HRCT chest at the time (±90 days) of baseline PFT. Those with limited disease on HRCT and less than 10% decline in FVC over one year had the best event-free survival and those with extensive disease on HRCT and greater than 10% decline in FVC had the worst outcome.
Discussion
We have previously shown that age, the extent of disease on HRCT chest, FVC and KCO on serial PFTs are significantly associated with outcome (a compos- ite of decline and death) in our Australian cohort (7) . In this report, we evaluated the relationship between change in PFT variables in the first 1 to 4 years following baseline PFT, and outcome.
We It is generally accepted that in patients with severe SSc-ILD, the decline in FVC is greatest early in the disease and tends to plateau after 4-6 years (3, 15) .
In the Scleroderma Lung Study (SLS), which included patients with SSc-ILD of up to four years' duration, the rate of decline was greatest in patients with more extensive disease on HRCT, especially in patients with duration of ILD less than 2 years, although the mean annual decline in FVC % predicted in the placebo group was less than 10%, irrespective of disease duration (16) . One possible explanation for DLCO and KCO decline being more strongly and robustly associated with outcome in our study than FVC decline may be the 'prevalent' nature of the cohort, where mean disease duration at baseline PFT was 12.2 years. Another likely explanation is that DLCO and especially KCO, which represents diffusing capacity corrected for alveolar volume, reflect the development of pulmonary vascular disease, an important contributor to poor outcome for patients with ILD, either in addition or secondary to the ILD. In IPF, change in FVC has been associated with mortality in many cohorts (17) (18) (19) although it is variously analysed as a continuous variable or according to a certain threshold. A decline in the percentage predicted value from baseline for FVC of 10% or more over six or 12 months is an independent predictor of mortality (20) but changes of this magnitude may be insensitive for real disease progression as smaller decreases in FVC of 5-10% predict survival and have been statistically significant primary endpoints in clinical trials (17, 21) . Indeed, the estimated minimum clinically important difference for percentage predicted FVC is only 2-6%. Furthermore, a relative decline in the absolute percentage predicted value may be more sensitive for detecting a decline in FVC, for example by 10% or more, than an absolute decline and with a similar predictive accuracy for outcome (22) . The threshold values for decline in FVC (10%), DLCO and KCO (both 15%) found in our study are the same as those validated in IPF (20) . Although smaller declines in FVC and KCO are also predictive of outcome in ILD, this has not been replicated in SSc-ILD, perhaps due to the slower rate of progression in the latter (21) . However, the NPV of stable PFTs indicates that even a smaller decline in PFT variables may be significant in SSc-ILD. In our study, the relatively long duration of disease at baseline PFT contrasts the report by Steen et al., where those with decline in lung function in the first 4 years following SSc diagnosis had the worst outcomes (3). We envisage three possible explanations for this observation. The first is that our cohort comprised a relatively larger number of patients with limited disease, in whom ILD may be diagnosed later in the disease course. Secondly, there may be an element of survivor bias in our 'prevalent' cohort, wherein no limitations were placed on disease duration at recruitment. As such, patients with severe diffuse disease and ILD may have died before being recruited. Finally, 'baseline' PFTs in this study were the first available set that could be retrieved for analysis, and may have been some time after the true onset or diagnosis of ILD.
In this observational study, we are unable to evaluate the effect of therapy on ILD outcomes as treatment assignment was not random and subject to confounding by indication. The effect of therapy on SSc-ILD is the subject of current and future clinical trials.
In conclusion, the course that SSc-ILD takes is evident within the first 1-4 years of follow-up. Patients who have no decline in PFTs over 4 years follow-up have better outcomes. As in IPF, a oneyear decline in DLCO or KCO of 15% or more, or in FVC of 10% or more is a poor prognostic marker and identifies patients who should be monitored more closely and considered for therapy. This provides a simple "rule of thumb" assessment of SSc-ILD that could complement the HRCT grading system for determining prognosis in SSc-ILD.
